Picture loading failed.

Anti-CXCR4 therapeutic antibody (Pre-made Ulocuplumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Ulocuplumab (INN; development code MDX-1338) is a monoclonal antibody designed for the treatment of hematologic malignancies.

Order informatioin

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-600-1mg 1mg 3090
GMP-Bios-ab-600-10mg 10mg 21890
GMP-Bios-ab-600-100mg 100mg 148000
GMP-Bios-ab-600-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-CXCR4 therapeutic antibody (Pre-made Ulocuplumab biosimilar,Whole mAb)
INN Name Ulocuplumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2013
Year Recommended2014
CompaniesBristol-Myers Squibb;Medarex;University of Bari
Conditions Approvedna
Conditions ActiveAcute myeloid leukaemia;Solid tumours;Waldenstrom's macroglobulinaemia;Neuroectodermal tumours
Conditions DiscontinuedB-cell lymphoma;B-cell prolymphocytic leukaemia;Precursor cell lymphoblastic leukaemia-lymphoma;Multiple myeloma
Development Techna